Union Bancaire Privee UBP SA Takes $7.25 Million Position in Astera Labs, Inc. $ALAB

Union Bancaire Privee UBP SA acquired a new stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 37,012 shares of the company’s stock, valued at approximately $7,247,000.

A number of other hedge funds also recently bought and sold shares of the stock. Great Valley Advisor Group Inc. increased its holdings in shares of Astera Labs by 2.2% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company’s stock valued at $372,000 after acquiring an additional 90 shares during the period. Straight Path Wealth Management boosted its position in Astera Labs by 1.5% during the second quarter. Straight Path Wealth Management now owns 6,850 shares of the company’s stock valued at $619,000 after purchasing an additional 100 shares in the last quarter. First Horizon Advisors Inc. boosted its position in Astera Labs by 12.4% during the second quarter. First Horizon Advisors Inc. now owns 982 shares of the company’s stock valued at $89,000 after purchasing an additional 108 shares in the last quarter. Advisors Asset Management Inc. grew its stake in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after purchasing an additional 194 shares during the last quarter. Finally, Berbice Capital Management LLC raised its holdings in Astera Labs by 14.3% in the second quarter. Berbice Capital Management LLC now owns 1,600 shares of the company’s stock worth $145,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other news, COO Sanjay Gajendra sold 90,459 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $13,088,512.71. Following the sale, the chief operating officer directly owned 1,599,750 shares of the company’s stock, valued at $231,467,827.50. This represents a 5.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Philip Mazzara sold 4,620 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $144.69, for a total transaction of $668,467.80. Following the completion of the sale, the general counsel owned 147,040 shares in the company, valued at $21,275,217.60. The trade was a 3.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 586,936 shares of company stock valued at $89,331,140 over the last quarter. Company insiders own 12.50% of the company’s stock.

Astera Labs Price Performance

NASDAQ ALAB opened at $144.94 on Wednesday. The company has a market cap of $24.48 billion, a price-to-earnings ratio of 130.58, a PEG ratio of 2.68 and a beta of 1.51. The stock’s fifty day moving average price is $163.73 and its 200 day moving average price is $154.73. Astera Labs, Inc. has a 1 year low of $47.13 and a 1 year high of $262.90.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.10. The business had revenue of $230.58 million for the quarter, compared to the consensus estimate of $206.42 million. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The company’s quarterly revenue was up 103.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.23 EPS. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Research analysts expect that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wall Street Zen lowered shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. BNP Paribas assumed coverage on shares of Astera Labs in a research report on Thursday, November 20th. They set an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft raised their target price on shares of Astera Labs from $160.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astera Labs in a research report on Wednesday, December 3rd. Finally, Stifel Nicolaus raised their price objective on Astera Labs from $185.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, Astera Labs currently has an average rating of “Moderate Buy” and a consensus price target of $188.17.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.